Centessa Pharmaceuticals (CNTA) Operating Leases (2023 - 2026)

Centessa Pharmaceuticals (CNTA) has 4 years of Operating Leases data on file, last reported at $7.4 million in Q1 2026.

• Quarterly Operating Leases fell 15.69% year-over-year to $7.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.4 million (down 15.69% YoY) and the FY2025 annual result came in at $7.6 million, down 8.6% from the prior year.
• Operating Leases slipped to $7.4 million in Q1 2026 per CNTA's latest filing, from $7.6 million in the prior quarter.
• Across five years, Operating Leases topped out at $9.3 million in Q1 2023 and bottomed at $7.4 million in Q1 2026.
• The 4-year median for Operating Leases is $8.7 million (2024), against an average of $8.5 million.
• The widest annual swing landed in 2024, when Operating Leases changed 0.0%; it then slipped 15.69% in 2026.
• Tracing CNTA's Operating Leases over 4 years: stood at $8.9 million in 2023, then decreased by 6.77% to $8.3 million in 2024, then slipped by 8.6% to $7.6 million in 2025, then decreased by 2.65% to $7.4 million in 2026.
• Per Business Quant, the three latest CNTA Operating Leases figures stand at $7.4 million (Q1 2026), $7.6 million (Q4 2025), and $7.8 million (Q3 2025).

Peer Comparison